| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Catalyst Biosciences Inc (F: HGF2)
HGF2 Technical Analysis
5
| As on 30th Oct 2023 HGF2 STOCK Price closed @ 7.40 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.84 & Strong Buy for SHORT-TERM with Stoploss of 1.30 we also expect STOCK to react on Following IMPORTANT LEVELS. |
HGF2STOCK Price
| Open | 7.40 | Change | Price | % |
| High | 7.40 | 1 Day | 6.90 | 1380.00 |
| Low | 7.40 | 1 Week | 7.02 | 1847.37 |
| Close | 7.40 | 1 Month | 6.89 | 1350.98 |
| Volume | 345 | 1 Year | 7.15 | 2860.00 |
| 52 Week High 2.04 | 52 Week Low 0.16 | ||||
F Germany Most Active Stocks
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| HGF2 Daily Charts |
HGF2 Intraday Charts |
Whats New @ Bazaartrend |
HGF2 Free Analysis |
|
|
HGF2 Important Levels Intraday
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
| RESISTANCE | 7.40 |
HGF2 Forecast November 2024
| 4th UP Forecast | 8.71 |
| 3rd UP Forecast | 8.29 |
| 2nd UP Forecast | 8.03 |
| 1st UP Forecast | 7.77 |
| 1st DOWN Forecast | 7.03 |
| 2nd DOWN Forecast | 6.77 |
| 3rd DOWN Forecast | 6.51 |
| 4th DOWN Forecast | 6.09 |
HGF2 Weekly Forecast
| 4th UP Forecast | 9.33 |
| 3rd UP Forecast | 8.71 |
| 2nd UP Forecast | 8.33 |
| 1st UP Forecast | 7.95 |
| 1st DOWN Forecast | 6.86 |
| 2nd DOWN Forecast | 6.47 |
| 3rd DOWN Forecast | 6.09 |
| 4th DOWN Forecast | 5.47 |
HGF2 Forecast2024
| 4th UP Forecast | 21.35 |
| 3rd UP Forecast | 16.88 |
| 2nd UP Forecast | 14.11 |
| 1st UP Forecast | 11.35 |
| 1st DOWN Forecast | 3.45 |
| 2nd DOWN Forecast | 0.69 |
| 3rd DOWN Forecast | -2.08 |
| 4th DOWN Forecast | -6.55 |
Catalyst Biosciences Inc ( F Germany Symbol : HGF2 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
HGF2 Business Profile
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service